Date: 2019-11-26
Type of information: Nomination
Compound: member of the board
Company: Sangamo Therapeutics (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 26, 2019, Sangamo Therapeutics, announced the appointment of James R. Meyers, an accomplished pharmaceutical executive with three decades of commercial experience, to the Company's Board of Directors. Mr. Meyers has over 30 years of commercial leadership experience in the biotechnology industry and worked at Gilead from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.
Financial terms:
Latest news:
Is general: Yes
